Company intelligence / Profile preview
Amygdala Neurosciences
San Francisco / Palo Alto, California, United Statesamygns.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Amygdala Neurosciences has advanced two proprietary small molecule ALDH2 inhibitors—ANS‑6637 and ANS‑858—for the treatment of substance use disorders. ANS‑6637 has completed extensive Phase 1 studies in over 150 subjects and entered multiple NIH-funded Phase 2 trials targeting alcohol, opioid, nicotine, and cocaine dependence. Preclinical data show reduction in drug-seeking behavior across several addiction models. The company recently selected ANS‑858 as its next clinical candidate with IND-enabling work underway for first-in-human studies targeting craving reduction in SUDs.[3][6][8]
Early clinical results indicate safety/tolerability with ongoing efficacy evaluation.
Pipeline breadth: At least two main programs identified.
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (notably selective and reversible ALDH2 inhibitors)[3][6][8]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
National Institutes of Health/NIAAA/NIH HEAL InitiativeInstitute of Human Virology at University of Maryland School of MedicineNIH Clinical Center [8][10]
Beyond the preview
Go deeper on Amygdala Neurosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amygdala Neurosciences.